Swiss & European Indices Rise on Novartis Momentum, Reaching Year‑Highs
Swiss and European indices climb, powered by Novartis gains and solid earnings, keeping markets optimistic after unchanged interest‑rate news.
2 minutes to read
NOVARTIS AG
Novartis Shares Hold Strong in Swiss & European Indices Amid Positive Remibrutinib Results
Novartis AG maintains a strong position in Swiss and European indices, with steady liquidity and recent phase‑III success for Remibrutinib boosting investor confidence.
2 minutes to read
Novartis: Defensive Growth, Patent Strategy & M&A Moves Propel Investor Confidence
Discover why Novartis’ solid balance sheet, digital health gains, and strategic M&A give investors a defensive edge in 2024’s pharma landscape.
4 minutes to read
Novartis Secures FDA Approval for Rhapsido’s Dual Indication, Boosting Uricaria Market Share by 2.7 M Patients
Novartis expands Rhapsido’s reach with FDA approval for symptomatic dermographism, boosting market share, revenue, and payer value in chronic urticaria.
5 minutes to read